文献速递免疫规划卫生政策与健康促进

减毒活疫苗能否更好地控制COVID-19?

Could live attenuated vaccines better control COVID-19?
PubMed 文献 · Vaccine · 2021-08-11

本文综述了已获批SARS-CoV-2疫苗(mRNA疫苗、腺病毒载体疫苗和灭活疫苗)的特点及优缺点,讨论了mRNA疫苗引起发热、腺病毒载体疫苗预存免疫与血栓风险、载体抗体削弱加强接种效果、灭活疫苗对变异株的效力等问题。作者介绍了其团队分离的温度敏感株作为减毒活疫苗候选株,并提出疫苗使用应结合有效性及疫情阶段进行优化。

要点

  • mRNA疫苗、腺病毒载体疫苗、灭活疫苗各有不良反应与效力局限
  • 作者团队分离出温度敏感株,可能作为减毒活疫苗的种子
  • 疫苗选择宜兼顾有效性与疫情阶段,而非仅看效力

核心结论

  • 减毒活疫苗可模拟自然感染且不带来疾病负担,被视为最有效的疫苗形式之一。
  • 作者团队已分离出可用作减毒活疫苗种子的温度敏感株,可作为COVID-19疫苗的补充选项。
  • 疫苗的使用策略应基于有效性并结合疫情阶段进行优化,而非仅依据效力。

研究设计与样本

  • 本文为综述,汇总已获批SARS-CoV-2疫苗的特点并讨论其优缺点。
  • 作者在文中介绍了其团队新分离的SARS-CoV-2温度敏感变异株及其作为减毒活疫苗的应用潜力。

主要发现

  • mRNA疫苗存在引起发热等不良反应的担忧。
  • 腺病毒载体疫苗面临针对腺病毒的预存免疫及可能参与血栓形成的担忧。
  • 针对腺病毒载体本身的抗体诱导会削弱加强接种的效果。
  • 以诱导体液免疫为主的灭活疫苗对新生变异株是否有效受到质疑,部分分离株对COVID-19康复者血清具有抵抗力。
  • 全球接种人数稳步增加,但仍需开发疫苗应对上述困难与担忧。

临床怎么用

  • 疫苗使用应不仅依据效力,还应结合疫情不同阶段进行优化,以指导接种实践。
  • 减毒活疫苗可作为现有SARS-CoV-2疫苗组合之外的补充选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In an effort to control the COVID-19 pandemic, large-scale vaccination is being implemented in various countries using anti-SARS-CoV-2 vaccines based on mRNAs, adenovirus vectors, and inactivated viruses. However, there are concerns regarding adverse effects, such as the induction of fever attributed to mRNA vaccines and pre-existing immunity against adenovirus vectored vaccines or their possible involvement in the development of thrombosis. The induction of antibodies against the adenovirus vector itself constitutes another hindrance, rendering boosting vaccinations ineffective. Additionally, it has been questioned whether inactivated vaccines that predominantly induce humoral immunity are effective against newly arising variants, as some isolated strains were found to be resistant to the serum from COVID-19-recovered patients. Although the number of vaccinated people is steadily increasing on a global scale, it is still necessary to develop vaccines to address the difficulties and concerns mentioned above. Among the various vaccine modalities, live attenuated vaccines have been considered the most effective, since they closely replicate a natural infection without the burden of the disease. In our attempt to provide an additional option to the repertoire of COVID-19 vaccines, we succeeded in isolating temperature-sensitive strains with unique phenotypes that could serve as seeds for a live attenuated vaccine. In this review article, we summarize the characteristics of the currently approved SARS-CoV-2 vaccines and discuss their advantages and disadvantages. In particular, we focus on the novel temperature-sensitive variants of SARS-CoV-2 that we have recently isolated, and their potential application as live-attenuated vaccines. Based on a thorough evaluation of the different vaccine modalities, we argue that it is important to optimize usage not only based on efficacy, but also on the phases of the pandemic. Our findings can be used to inform vaccination practices and improve global recovery from the COVID-19 pandemic.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Okamura S, Ebina H. Could live attenuated vaccines better control COVID-19? Vaccine. 2021. PMID: 34426024. doi:10.1016/j.vaccine.2021.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。